

Phenomics Health Combines Multiple Precision Medicine Products for Medication Selection, Dose Tailoring and Monitoring

Personalized Medication Products for Mental Illness, Pain and Cardiovascular Disorders

PLYMOUTH, MI, UNITED STATES, May 23, 2022 /EINPresswire.com/ --

Phenomics Health Inc., a bioinformatics-based [precision medicine](#) company, today announced the commercial integration of six PreciMed® pharmacometabolomic (PMx) and PredictScript™ pharmacogenomic (PGx) clinical products to comprehensively support patient medication treatment. Phenomics Health novel product platforms can now provide clinicians with multiple tools to enhance treatment outcomes through personalized medication selection, direct measurement of patient medications, dose optimization, and periodic monitoring of patient medication adherence, safety, and efficacy.



“

Phenomics Health is the only precision medicine company to combine medication prediction and measurement to improve patient treatment outcomes.”

Pamela Weir

PreciMed and PredictScript products cover patient medication selection and response monitoring across the most significant disease and medication treatment classes: mental illness, cardiovascular, metabolic, and pain disorders.

Phenomics Health is the only precision medicine company to combine drug prediction with actual drug measurement to inform patients and caregivers about effective treatment regimens using both pharmacogenomics (PGx)

and pharmacometabolomics (PMx) product platforms. Phenomics Health products are supported by multiple issued/pending patents, publications, and clinical studies.

“Combining PreciMed and PredictScript commercial products represents a substantial

improvement in precision medicine by helping clinicians and health systems identify and select appropriate medications, drug combinations, and drug doses. Phenomics Health products provide accurate, reproducible, personalized drug selection with periodic monitoring of patient drug adherence to improve drug efficacy, reduce adverse drug reactions, recommend effective drug combinations, and improve patient outcomes,” said Pamela Weir, President and Chief Operating Officer of Phenomics Health.

About PreciMed and PredictScript Products

Phenomics Health patented PreciMed pharmacometabolomics products can identify and quantify >230 drugs in a patient’s circulation to monitor drug adherence, provide a reconciliation of actual medications taken, guide dose-tailoring, identify harmful drug-drug interactions, and avoid adverse drug reactions. PreciMed includes four comprehensive medication management products that can measure actual medications in a patient’s circulation, including: 1) SyncViewRx, which can definitively identify 211 prescription and OTC medications; 2) PreciViewCNS, which can quantify 87 antidepressant, antipsychotic, anxiety, and chronic pain medications; 3) SyncViewPAIN, which can definitively identify 101 psychotropics, neurologic agents, opioids, and benzodiazepine medications; and 4) PreciMed PMP, which can quantitate 232 medications and analytes in a patient’s circulation across multiple therapeutic categories. PreciMed PMx technology has already been utilized in over 10,000 patients in the U.S.

Phenomics Health [PredictScript pharmacogenomics](#) technology includes two comprehensive medication prediction products that help clinicians select appropriate medications for individual patients, including: 1) PredictScriptPOLY, which covers a broad spectrum of genetic variants across 140 frequently prescribed antidepressants, antipsychotics, anticonvulsants, pain, cardiovascular, metabolic, and gastrointestinal medications; and 2) PredictScriptCNS, which covers genetic variants across 94 of the most prescribed depression, anxiety, bipolar disorder, schizophrenia, and pain medications. PreciMed and PredictScript products are covered by Medicare, Medicaid, and commercial payors.

Critical Need for Precision Medicine

Stress, anxiety, pain, CNS, and cardiovascular/metabolic disorders represent some of the most significant health problems of the 21st century. According to the Center for Disease Control (CDC), over 50% of the U.S. population suffers from at least one chronic condition¹ and nearly 70% of Medicare beneficiaries suffer from 2 or more chronic conditions.² Globally, one in three adults suffer from multiple chronic conditions (MCC), including depression, diabetes, and cardiovascular disorders.³ Each MCC is associated with as many as 8 medications in older adults with a corresponding decrease in medication adherence.³

Stress is a major contributor to chronic physical and mental disorders. Over 70% of people experience stress that negatively affects their mental and physical health,⁴ with stress accounting for about 75% of all doctor visits.⁵ Predisposition and vulnerability to stress have both genetic and epigenetic origins. Further increases in stress related mental illnesses have resulted from the COVID-19 pandemic,⁶ including an increase in moderate to severe anxiety to

over 37% and moderate to severe depression to over 30% of the U.S. adult population,⁷ leading to likely increased generational prevalence.

“Increased pharmacogenomic drug predictability and precision drug pharmacometabolomic measurement provide the means to effectively manage mental health conditions and chronic disorder polypharmacy, identify specific medications to deprescribe, and monitor patient drug adherence and outcomes from informed prescribing. These are significant precision medicine advances that can help improve medication treatment for people who suffer from pain, cardiovascular, and CNS disorders. Precision prescribing and dose tailoring are essential to improving patient outcomes and lowering treatment costs,” said James S. Burns, Chairman and CEO of Phenomics Health.

About Phenomics Health

Phenomics Health Inc. (PHI) is a precision medicine company offering advanced clinical treatment decision support products and services to provide medication recommendations, anticipate adverse drug reactions, drug-gene and drug-drug interactions, and improve patient outcomes. Phenomics patented technologies are based on the emerging field of pharmacophenomics, incorporating genetic, epigenetic, panomic, pharmacometabolomics, systems biology, electronic health record (EHR), sociomics™, and other clinically relevant patient data. Phenomics patented pharmacogenomics technology utilizes artificial intelligence and machine learning to predict drug response phenotypes for individual patients based on an expanded paradigm of gene regulation in which the regulatory and spatial genome networks play a prominent role. Networks containing disease risk, drug response, and adverse event variants form the foundation for Phenomics Health’s development of novel pharmacogenomic clinical treatment decision support products. Phenomics Health patented PreciMed pharmacometabolomic products can identify and quantify >230 drugs in a patient’s circulation to monitor drug adherence, provide an accurate reconciliation of actual medications taken, guide dose-tailoring, identify harmful drug-drug interactions, and avoid adverse drug reactions. Visit www.phenomicshealth.com for more information.

For additional information, please contact:


Pamela Weir

President and Chief Operating Officer

Phenomics Health Inc.

734.233.3070

info@phenomicshealth.com

1.Boersma P, Black LI, Ward BW. Prevalence of Multiple Chronic Conditions Among US Adults, 2018. *Prev Chronic Dis* 2020;17:200130. DOI: <http://dx.doi.org/10.5888/pcd17.200130>

2.Öchner KA, Cox CS. Prevalence of Multiple Chronic Conditions Among Medicare Beneficiaries, United States, 2010. *Prev Chronic Dis* 2013;10:120137. DOI: <http://dx.doi.org/10.5888/pcd10.120137> .

3. Chronic disease is our biggest global health challenge | World Economic Forum (weforum.org)

4. Stress Facts, Statistics and Trends | The Recovery Village

5. Nerurkar, A., Bitton, A., Davis, R. B., Phillips, R. S., & Yeh, G. (2013). When physicians counsel about stress: results of a national study. JAMA internal medicine, 173(1), 76–77.

<https://doi.org/10.1001/2013.jamainternmed.480>

6. Stress in America™ 2020 (apa.org)

7. Mental Health Crisis during the COVID-19 Pandemic (tcf.org)

James Burns

Phenomics Health Inc.

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/572675758>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.